Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Regimen (LN-145/LN-144) in Pediatric and Young Adult Relapsed or Refractory Solid Tumors
NCT06566092Phase 1Terminated
- Sponsor
- Iovance Biotherapeutics
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of LN-145 and lifileucel in rhabdomyosarcoma (RMS), Ewing sarcoma, primary central nervous system tumor and 1 more (4 arms), sponsored by Iovance Biotherapeutics. Primary endpoint: Incidence rate of Treatment-Emergent Adverse Events up to 24 months. Started Mar 2024; status: terminated.
02
Drugs
LN-145lifileucel
03
Conditions
rhabdomyosarcoma (RMS)Ewing sarcomaprimary central nervous system tumormelanoma
Beyond the preview
Go deeper on NCT06566092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566092.